Literature DB >> 12495789

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.

Evgeny Krupitsky1, Andrey Burakov, Tatyana Romanova, Igor Dunaevsky, Rick Strassman, Alexander Grinenko.   

Abstract

Seventy detoxified heroin-addicted patients were randomly assigned to one of two groups receiving ketamine psychotherapy (KPT) involving two different doses of ketamine. The patients of the experimental group received existentially oriented psychotherapy in combination with a hallucinogenic ("psychedelic") dose of ketamine (2.0 mg/kg im). The patients of the control group received the same psychotherapy combined with a low, non-hallucinogenic (non-psychedelic), dose of ketamine (0.2 mg/kg im). Both the psychotherapist and patient were blind to the dose of ketamine. The therapy included preparation for the ketamine session, the ketamine session itself, and the post session psychotherapy aimed to help patients to integrate insights from their ketamine session into everyday life. The results of this double blind randomized clinical trial of KPT for heroin addiction showed that high dose (2.0 mg/kg) KPT elicits a full psychedelic experience in heroin addicts as assessed quantitatively by the Hallucinogen Rating Scale. On the other hand, low dose KPT (0.2 mg/kg) elicits "sub-psychedelic" experiences and functions as ketamine-facilitated guided imagery. High dose KPT produced a significantly greater rate of abstinence in heroin addicts within the first two years of follow-up, a greater and longer-lasting reduction in craving for heroin, as well as greater positive change in nonverbal unconscious emotional attitudes than did low dose KPT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495789     DOI: 10.1016/s0740-5472(02)00275-1

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  38 in total

Review 1.  Hallucinogens: an update.

Authors:  John H Halpern
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 2.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

3.  A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Authors:  E Dakwar; E V Nunes; C L Hart; M C Hu; R W Foltin; F R Levin
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

4.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

Review 5.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

6.  Dextromethorphan and bupropion reduces high level remifentanil self-administration in rats.

Authors:  Graham Blair; Corinne Wells; Ashley Ko; John Modarres; Caroline Pace; James M Davis; Amir H Rezvani; Jed E Rose; Edward D Levin
Journal:  Pharmacol Biochem Behav       Date:  2020-04-01       Impact factor: 3.533

7.  Therapeutic infusions of ketamine: do the psychoactive effects matter?

Authors:  E Dakwar; C Anerella; C L Hart; F R Levin; S J Mathew; E V Nunes
Journal:  Drug Alcohol Depend       Date:  2014-01-15       Impact factor: 4.492

8.  Acute and post-acute behavioral and psychological effects of salvinorin A in humans.

Authors:  Peter H Addy
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

Review 9.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

10.  Heroin self-administration: II. CNS gene expression following withdrawal and cue-induced drug-seeking behavior.

Authors:  Kara L Kuntz; Kruti M Patel; Patricia S Grigson; Willard M Freeman; Kent E Vrana
Journal:  Pharmacol Biochem Behav       Date:  2008-04-03       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.